One Dose of an Inhaled Psychedelic Eased Hard-to-Treat Depression

Q: How is GH001 different from regular antidepressants?

Standard antidepressants are pills you take daily, and they often take several weeks to show any benefit. GH001 is an inhaled psychedelic given on a single day in a clinic, as an individualized regimen of up to three escalating doses one hour apart, and the improvement was measured by day 8 in this trial. The psychoactive effects themselves were brief, with a median of 9 to 14 minutes per dose. This faster timeline is one of the main reasons researchers are interested in it.

Q: Does a 57.5 percent remission rate mean it will work for most people?

It is a very promising number, but it comes from one phase 2b trial of 81 patients measured at day 8. Remission of 57.5 percent compared with 0 percent on placebo is unusually strong, yet larger studies are needed to show how reliably it works across different patients. Every patient in this trial was white, and all were between 18 and 64 with a current episode of two years or less, so the tested population was narrow. Treat the result as encouraging early evidence, not a final answer.

Q: Is inhaled 5-MeO-DMT safe?

In this trial, all adverse events were mild or moderate, with none severe or serious, and no one stopped treatment because of them. Nausea was the most common, in 42.5 percent of GH001 patients. That is reassuring, but the placebo-controlled period was small and lasted 7 days, so rare or longer-term risks may not show up yet. Psychedelics like this are given under medical supervision in a controlled setting for a reason. Using them outside of a clinic carries real risks and is not what this research supports.

Can a single-day course of an inhaled psychedelic lift depression that drugs have failed to treat?

Yes. In this trial, a single-day regimen of an inhaled psychedelic called GH001 put more than half of patients with hard-to-treat depression into remission within a week, while placebo put none. The GH001 group beat placebo by 15.5 points on a standard depression scale, a very large effect.

Treatment-resistant depression means standard antidepressants have not worked, often after several tries. It affects millions of people and can feel hopeless. So a single-day treatment that works this fast is a big deal, and that is exactly what researchers set out to test here.

What is GH001?

GH001 is an inhaled, short-acting form of a psychedelic compound called 5-MeO-DMT, also known as mebufotenin. Patients breathe it in during a single dosing day in a clinic. In this trial the psychoactive effects had a median duration of 9 to 14 minutes depending on the dose, so the experience is short. This is different from daily pills that you take for weeks or months before you know if they help.

Importantly, this was not one fixed dose. Patients received an individualized dosing regimen of up to three escalating doses of 6, 12, and 18 mg, given one hour apart on the same day. A further dose was given only if the previous one was well tolerated and the patient had not already reached an intense psychoactive effect. In practice, 9 of 40 patients (22.5 percent) received a single dose, 21 (52.5 percent) received two, and 10 (25 percent) received all three.

What the data show

The results were striking. This phase 2b trial enrolled 81 adults aged 18 to 64 with treatment-resistant depression at 16 European sites, running from May 2023 to March 2025. Treatment resistance was defined as nonresponse to two to five oral antidepressant treatments, with a current episode lasting up to two years. Each person was randomly assigned to GH001 (40 patients) or placebo (41 patients) in a single dosing day.

By day 8, the change in MADRS score, a widely used depression rating scale, favored GH001 over placebo by 15.5 points (least squares mean difference, standard error 1.7, p < .001). Patients started with mean MADRS scores of 29.0 in the GH001 group and 28.2 in the placebo group, so a 15.5-point separation is a large share of the baseline severity.

The size of that gap matters. The effect size was a Cohen’s d of -2.0, which counts as a very large effect in medical research.

Remission was the most remarkable number. Among GH001 patients, 23 of 40 (57.5 percent) reached remission, defined as a MADRS score of 10 or below. In the placebo group, 0 of 41 (0 percent) did.

Secondary measures moved in the same direction. Anxiety scores on the HAM-A favored GH001 by 10.0 points (95 percent CI, -12.4 to -7.7). Clinician-rated illness severity on the CGI-S favored GH001 by 2.5 points (95 percent CI, -3.0 to -2.1). Quality of life on the Q-LES-Q-SF favored GH001 by 21.4 points (95 percent CI, 17.3 to 25.4).

Dr. Kumar’s Take

I find this study really exciting, and I want to be careful at the same time. A single-day treatment that pushes more than half of hard-to-treat patients into remission within a week, against zero on placebo, is the kind of result I rarely see in psychiatry. An effect size of -2.0 is unusual in any depression trial I read.

I would also be precise about what was tested. This was not one inhalation. It was an individualized escalating regimen on one day, with most patients needing two or three doses, and that titration is part of why it worked. Any future rollout would have to reproduce that structure, including the clinical judgement about whether to escalate.

That said, this is a phase 2b trial with 81 people and a primary readout at day 8. Every patient enrolled was white, which limits how far I would generalize. There was also a plausible route to functional unblinding, since the drug produces obvious psychoactive effects; the investigators used remote, blinded independent raters for MADRS to guard against that, but it remains a real consideration. Psychedelic treatments need careful clinical settings and monitoring. I would not want anyone reading this to seek out 5-MeO-DMT on their own. The promise here is real, but it belongs in supervised trials for now.

How the study was done

This was a double-blind, randomized, placebo-controlled trial, which is the gold standard in medical research. Double-blind means the patients and the site staff handling treatment, assessments, and care did not know who got the real drug and who got placebo, which helps prevent expectations from skewing the results. Randomized means people were assigned to each group by chance, 1:1.

Patients received treatment on a single dosing day, and the primary outcome was the change in MADRS score from baseline to day 8. Antidepressants, antipsychotics, and drugs with monoamine oxidase inhibitor activity were prohibited during the trial and for two weeks before baseline, and starting or changing psychotherapy was also prohibited, so the comparison isolates the drug itself. To protect the blind further, MADRS was administered remotely by independent raters who had no role in screening, dosing, safety data, or patient care, and who could not access patient safety records. Using placebo as the comparison makes the 0 percent remission rate in that group a useful benchmark for how powerful the GH001 effect really was. All patients then rolled into a 6-month open-label extension, which is being reported separately.

Safety, limits, and caveats

On safety, the early picture looks reassuring. Adverse events occurred in 29 of 40 GH001 patients (72.5 percent) versus 3 of 41 on placebo (7.3 percent), but every one of them was mild or moderate. There were no severe adverse events, no serious adverse events, no deaths, and no one discontinued because of side effects. The most common were nausea (42.5 percent), salivary hypersecretion (20 percent), and paresthesia, meaning tingling or pins and needles (20 percent). For a psychedelic given in a clinic, that is encouraging.

Still, the limits are important. The trial was small and the placebo-controlled comparison ran only to day 8. Larger and longer trials are the next step before this could become a real treatment option.

Practical Takeaways

Do not try to obtain 5-MeO-DMT or any psychedelic on your own, since these results come from a controlled clinical trial with medical supervision, not at-home use.
If you have depression that has not responded to standard medications, ask your psychiatrist about clinical trials of psychedelic-assisted treatments you might qualify for.
Understand what “single-day treatment” actually meant here: an escalating regimen of up to three inhaled doses an hour apart, with most patients receiving two or three.
Keep your expectations measured, because this is an early phase 2b study and larger trials with longer placebo-controlled follow-up are still needed.

FAQs

How is GH001 different from regular antidepressants?

Standard antidepressants are pills you take daily, and they often take several weeks to show any benefit. GH001 is an inhaled psychedelic given on a single day in a clinic, as an individualized regimen of up to three escalating doses one hour apart, and the improvement was measured by day 8 in this trial. The psychoactive effects themselves were brief, with a median of 9 to 14 minutes per dose. This faster timeline is one of the main reasons researchers are interested in it.

Does a 57.5 percent remission rate mean it will work for most people?

It is a very promising number, but it comes from one phase 2b trial of 81 patients measured at day 8. Remission of 57.5 percent compared with 0 percent on placebo is unusually strong, yet larger studies are needed to show how reliably it works across different patients. Every patient in this trial was white, and all were between 18 and 64 with a current episode of two years or less, so the tested population was narrow. Treat the result as encouraging early evidence, not a final answer.

Is inhaled 5-MeO-DMT safe?

In this trial, all adverse events were mild or moderate, with none severe or serious, and no one stopped treatment because of them. Nausea was the most common, in 42.5 percent of GH001 patients. That is reassuring, but the placebo-controlled period was small and lasted 7 days, so rare or longer-term risks may not show up yet. Psychedelics like this are given under medical supervision in a controlled setting for a reason. Using them outside of a clinic carries real risks and is not what this research supports.

Bottom Line

A single-day individualized regimen of the inhaled psychedelic GH001, up to three escalating doses given an hour apart, produced a large and fast improvement in patients with treatment-resistant depression: 23 of 40 patients (57.5 percent) reached remission by day 8 compared with none of the 41 on placebo, and the group difference on MADRS was 15.5 points with an effect size of -2.0. Early safety looks good, with no severe or serious adverse events. This is one of the more promising depression results in recent years, but it is still an early trial that needs larger studies and longer placebo-controlled follow-up before it can reach patients.

Read the full study